ARCHIVES
VOL. 10, ISSUE 11 (2025)
In Silico screening and evaluation of antimalarial drugs and analogues against critical malarial targets
Authors
Priyanka Dash, Sunita Patra, Subha Shree Satapathy, Subhasmita Pattnaik, Santhosh Goud, Subasini Patnaik
Abstract
Malaria remains a global health challenge,
with rising drug resistance in Plasmodium parasites and insecticide
resistance in vectors exacerbating the burden. Plasmodium falciparum,
the deadliest species, is the primary cause of severe malaria and related
deaths. Resistance to widely used antimalarials such as chloroquine,
primaquine, mefloquine, and proguanil has rendered these treatments
increasingly ineffective, highlighting the need for novel therapeutic
strategies. This study utilizes an in-silico approach to identify
analogues of these drugs, targeting key parasite proteins, including Pf CRT,
Fe-II protoporphyrin IX, and Pf TS-DHFR. Molecular docking was employed
to evaluate binding affinities and identify promising lead compounds with
enhanced efficacy and reduced resistance potential. Integrating genomic and
bioinformatics data facilitated the identification of parasite-specific targets
essential for survival, minimizing off-target effects and resistance risks. The
findings propose optimized formulations for targeted drug delivery, enhancing
therapeutic efficacy while reducing side effects. This work underscores the
role of bioinformatics and rapid drug design techniques in accelerating the
discovery of safer, fast-acting, and cost-effective antimalarials to combat
drug-resistant malaria effectively.
Download
Pages:57-63
How to cite this article:
Priyanka Dash, Sunita Patra, Subha Shree Satapathy, Subhasmita Pattnaik, Santhosh Goud, Subasini Patnaik "<i>In Silico</i> screening and evaluation of antimalarial drugs and analogues against critical malarial targets". International Journal of Entomology Research, Vol 10, Issue 11, 2025, Pages 57-63
Download Author Certificate
Please enter the email address corresponding to this article submission to download your certificate.